HIGHLIGHTS
- who: Dave Singh from the Medicines Evaluation Unit, University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK have published the paper: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD, in the Journal: (JOURNAL) of 30/05/2017
- what: This study investigated the efficacy and safety of ensifentrine a first-in-class dual of PDE 3 and 4 in patients with COPD. The aim was to investigate the placebocorrected effect of ensifentrine on change from baseline in peak FEV1 (assessed over 0-3 h) on Week . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.